Risk factors and lethality associated with Candidemia in severe COVID-۱۹ patients

Publish Year: 1401
نوع سند: مقاله ژورنالی
زبان: English
View: 68

This Paper With 7 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_CUMM-8-1_006

تاریخ نمایه سازی: 11 آذر 1402

Abstract:

Background and Purpose: Candidemia remained important in the intensive care units(ICU) during the COVID-۱۹ pandemic. This study aimed to investigate the clinical and laboratory data on candidemia in COVID-۱۹ patients.Materials and Methods: The baseline characteristics, as well as laboratory and clinicalfindings of candidemia and non-candidemia patients, were compared. Candidemia was defined as the isolation of Candida spp. from blood cultures. The isolates were identified by VITEK® ۲ (bioMérieux, France) commercial method. Antifungal susceptibility was assessed using the E-test method. Univariate and multiple binary logistic regression analyses were performed to compare the variables.Results: In total, ۱۲۶ patients with the COVID-۱۹ disease were included. Candidemiawas diagnosed in ۴۴ (۳۵%) of the patients. The number of patients with diabetes mellitus and chronic renal failure was higher in the candidemia group. In the candidemia group, the duration of ICU stay of patients, the ۳۰-day mortality rate, mechanical ventilation therapy, and systemic corticosteroids (Prednisone) usage were significantly higher in candidemia patients. Moreover, the median white blood cell, neutrophils, and lactate dehydrogenase were higher in the candidemia group. Univariate and multiple binary logistic regression analyses were performed to compare the variables. Isolated species were identified as Candida albicans (n=۱۲, ۴۱%), Candida parapsilosis (n=۷, ۲۴%), Candida glabrata (n=۶, ۲۱%), Candida tropicalis (n=۳, ۱۰%), and Candida dublinensis (n=۱, ۳%). In total, three isolates of six C. glabrata species had dose-dependent sensitivity to fluconazole, and one C. parapsilosis was determined to be resistant.Conclusion: The COVID-۱۹ patients who are admitted to ICU have many risk factors associated with candidemia. The most common risk factors for the development of candidemia were mechanical ventilation, diabetes mellitus, neutrophilia, and low hemoglobin level. The most frequently isolated species was C. albicans. Moreover, caspofungin was found to be the most effective drug in vitro. No significant resistancepattern was detected against the isolated species. It should be noted that risk-stratified antifungal prophylaxis in the ICU is possible.

Authors

Zehra Beştepe Dursun

Health Science University, Kayseri Faculty of Medicine, Department of Infectious Diseases, Kayseri, Turkey

Hilal Sipahioğlu

Health Science University, Kayseri Faculty of Medicine, Department of Infectious Diseases, Kayseri, Turkey

Recep Civan Yüksel

Health Science University, Kayseri Faculty of Medicine, Department of Intensive Care Unit, Kayseri, Turkey

Hafize Sav

Health Science University, Kayseri Faculty of Medicine, Department of Mycology, Kayseri, Turkey

Ilhami Çelik

Health Science University, Kayseri Faculty of Medicine, Department of Infectious Diseases, Kayseri, Turkey

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Wang Y, Liao B, Guo Y, Li F, Lei C, ...
  • Cox MJ, Loman N, Bogaert D, O’Grady J. Co-infections: potentially ...
  • Medina N, Soto-Debrán JC, Seidel D, Akyar I, Badali H, ...
  • Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species ...
  • Kayaaslan B, Eser F, Kaya Kalem A, Bilgic Z, Asilturk ...
  • Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, ...
  • Mastrangelo A, Germinario BN, Ferrante M, Frangi C, Li Voti ...
  • World Health Organization. Clinical management of COVID-۱۹:interim guidance, ۲۷ May ...
  • Ai T, Yang Z, Hou H, Zhan C, Chen C, ...
  • Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, ...
  • Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: ...
  • ۱۹۸۵; ۱۳:۸۱۸-۲۹ ...
  • Jones AE, Trzeciak S, Kline JA. The Sequential Organ Failure ...
  • Zhao Q, Meng M, Kumar R, Wu Y, Huang J, ...
  • A Clinical and Laboratory Standards Institute, Reference Method for Broth ...
  • Bassetti M, Trecarichi EM, Righi E, Sanguinetti M, Bisio F, ...
  • Raja NS. Epidemiology, risk factors, treatment, and outcome of Candida ...
  • Chen PY, Chuang YC, Wang JT, Sheng WH, Yu CJ, ...
  • Bader MS, Lai SM, Kumar V, Hinthorn D. Candidemia in ...
  • Tang HJ, Liu WL, Lin HL, Lai CC. Epidemiology and ...
  • Hosseinikargar N, Basiri R, Asadzadeh M, Najafzadeh MJ, Zarrinfar H. ...
  • Loss SH, de Oliveira RP, Maccari JG, Savi A, Boniatti ...
  • Luo P, Liu Y, Qiu L, Liu X, Liu D, ...
  • Romani L, Mencacci A, Cenci E. Impaired neutrophil response and ...
  • Vand Enckevort FHJ, Netea MG, Hermus ARM. Increased susceptibility to ...
  • Antinori S, Bonazzetti C, Gubertini G, Capetti A, Pagani C, ...
  • Riche CVW, Cassol R, Pasqualotto AC. Is the Frequency of ...
  • Macauley P, Epelbaum O. Epidemiology and Mycology of Candidaemia in ...
  • Mastrangelo A, Germinario BN, Ferrante M, Frangi C, Li Voti ...
  • Nucci M, Barreiros G, Guimarães LF, Deriquehem VAS, Castiñeiras AC, ...
  • Trofa D, Attila G, Joshua DN. Candida parapsilosis, an emerging ...
  • نمایش کامل مراجع